
IOVA 8-DAY DEADLINE ALERT: Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor ...
SAN FRANCISCO, July 06, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025 …